71. Qiu L, Cheng W, Lin J, Luo S, Xue L, Pan J. Synthesis and biological evaluation of novel (99m)Tc-labeled bisphosphonates as superior bone imaging agents. Molecules. 2011;16(8):6165-78. 72. Rachel A. Powsner ERP, (Ed). Essential Nuclear Medicine Physics. Massachusetts: Blackwell Publishing Ltd.; 2006. 73. Rao DVNS. Novel procedure for the synthesis of 1-hydroxy-1,1-bisphosphonic acids using phenols as medium (vol 37, pg 4359, 2007). Synthetic Commun. 2008;38(3):473-. 74. Rao DVNS, Dandala R, Narayanan GKASS, Lenin R, Sivakumaran M, Naidu A. Novel procedure for the synthesis of 1-hydroxy-1,1-bisphosphonic acids using phenols as medium. Synthetic Commun. 2007;37(22-24):4359-65. 75. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. J Clin Invest. 1996;97(12):2692-6. 76. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer-Am Cancer Soc. 2000;88(12 Suppl):2961-78. 77. Rogers MJ, Watts DJ, Russell RGG. Overview of bisphosphonates. Cancer-Am Cancer Soc. 1997;80(8):1652-60. 78. Roohi S, Mushtaq A, Malik SA. Synthesis and biodistribution of Tc-99mVancomycin in a model of bacterial infection. Radiochim Acta. 2005;93(7):415-8. 79. Russell RGG. Bisphosphonates: The first 40 years. Bone. 2011;49(1):2-19. 80. Russell RGG, Croucher PI, Rogers MJ. Bisphosphonates: Pharmacology, mechanisms of action and clinical uses. Osteoporosis Int. 1999;9:66-80. 81. Russell RGG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res. 1999;14:53-65. 82. Saha GB. Fundamentals of Nuclear Pharmacy. 6th edition ed. Saha GB, editor. London: Springer; 2010. 83. Saha GB. Radionuclide Generators. Fundamentals of Nuclear Pharmacy, Sixth Edition. 2010:67-82. 84. Saha GB, Macintyre WJ, Go RT. Cyclotrons and Positron Emission Tomography Radiopharmaceuticals for Clinical Imaging. Semin Nucl Med. 1992;22(3):150-61. 85. Sampson CB, editor. Textbook of Radiopharmacy : theory and practice. Third Edition ed. Amsterdam: Gordon and Breach Science Publishers; 1999. 86. Santos-Oliveira R, Smith SW, Carneiro-Leao AMA. Radiopharmaceuticals drug interactions: a critical review. An Acad Bras Cienc. 2008;80(4):665-75. 87. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action – Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88(6):2095-105. 88. Savelli G, Maffioli L, Maccauro M, De Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45(1):27-37. 89. Schwochau K. Technetium Chemistry and Radiopharmaceutical Applications: Wiley; 1997. 90. Shikata E, Iguchi A. Application of Mo-99 to nuclear-medicine and ıts production. J Atom Energ Soc Jpn. 1984;26(8):662-70. 91. Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Brit J Haematol. 1997;98(3):665-72. 92. Shmerling RH, Goldring SR. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. Comment. Clin Exp Rheumatol. 2003;21(2):151-2. 93. Silverman SL, Maricic M. Recent developments in bisphosphonate therapy. Semin Arthritis Rheu. 2007;37(1):1-12. 94. Skerjanec A, Berenson J, Hsu CH, Major P, Miller WH, Ravera C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol. 2003;43(2):154-62.
143



156. SAYFAYA BENZER SAYFALAR

tabs_sener_yagiz_191898 - Sayfa
...


156. SAYFA ICERIGI

71. Qiu L, Cheng W, Lin J, Luo S, Xue L, Pan J. Synthesis and biological evaluation of novel (99m)Tc-labeled bisphosphonates as superior bone imaging agents. Molecules. 2011;16(8):6165-78. 72. Rachel A. Powsner ERP, (Ed). Essential Nuclear Medicine Physics. Massachusetts: Blackwell Publishing Ltd.; 2006. 73. Rao DVNS. Novel procedure for the synthesis of 1-hydroxy-1,1-bisphosphonic acids using phenols as medium (vol 37, pg 4359, 2007). Synthetic Commun. 2008;38(3):473-. 74. Rao DVNS, Dandala R, Narayanan GKASS, Lenin R, Sivakumaran M, Naidu A. Novel procedure for the synthesis of 1-hydroxy-1,1-bisphosphonic acids using phenols as medium. Synthetic Commun. 2007;37(22-24):4359-65. 75. Rodan GA, Fleisch HA. Bisphosphonates: Mechanisms of action. J Clin Invest. 1996;97(12):2692-6. 76. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer-Am Cancer Soc. 2000;88(12 Suppl):2961-78. 77. Rogers MJ, Watts DJ, Russell RGG. Overview of bisphosphonates. Cancer-Am Cancer Soc. 1997;80(8):1652-60. 78. Roohi S, Mushtaq A, Malik SA. Synthesis and biodistribution of Tc-99mVancomycin in a model of bacterial infection. Radiochim Acta. 2005;93(7):415-8. 79. Russell RGG. Bisphosphonates: The first 40 years. Bone. 2011;49(1):2-19. 80. Russell RGG, Croucher PI, Rogers MJ. Bisphosphonates: Pharmacology, mechanisms of action and clinical uses. Osteoporosis Int. 1999;9:66-80. 81. Russell RGG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res. 1999;14:53-65. 82. Saha GB. Fundamentals of Nuclear Pharmacy. 6th edition ed. Saha GB, editor. London: Springer; 2010. 83. Saha GB. Radionuclide Generators. Fundamentals of Nuclear Pharmacy, Sixth Edition. 2010:67-82. 84. Saha GB, Macintyre WJ, Go RT. Cyclotrons and Positron Emission Tomography Radiopharmaceuticals for Clinical Imaging. Semin Nucl Med. 1992;22(3):150-61. 85. Sampson CB, editor. Textbook of Radiopharmacy : theory and practice. Third Edition ed. Amsterdam: Gordon and Breach Science Publishers; 1999. 86. Santos-Oliveira R, Smith SW, Carneiro-Leao AMA. Radiopharmaceuticals drug interactions: a critical review. An Acad Bras Cienc. 2008;80(4):665-75. 87. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action – Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88(6):2095-105. 88. Savelli G, Maffioli L, Maccauro M, De Deckere E, Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med. 2001;45(1):27-37. 89. Schwochau K. Technetium Chemistry and Radiopharmaceutical Applications: Wiley; 1997. 90. Shikata E, Iguchi A. Application of Mo-99 to nuclear-medicine and ıts production. J Atom Energ Soc Jpn. 1984;26(8):662-70. 91. Shipman CM, Rogers MJ, Apperley JF, Graham R, Russell G, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Brit J Haematol. 1997;98(3):665-72. 92. Shmerling RH, Goldring SR. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. Comment. Clin Exp Rheumatol. 2003;21(2):151-2. 93. Silverman SL, Maricic M. Recent developments in bisphosphonate therapy. Semin Arthritis Rheu. 2007;37(1):1-12. 94. Skerjanec A, Berenson J, Hsu CH, Major P, Miller WH, Ravera C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol. 2003;43(2):154-62.
143




single.php